NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Bharath Kumar
AD Scientific Index 2024
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
Biogen Inc - / United States
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Bharath Kumar's MOST POPULAR ARTICLES
1-)
Two randomized phase 3 studies of aducanumab in early Alzheimer’s diseaseS Budd Haeberlein, PS Aisen, F Barkhof, S Chalkias, T Chen, S Cohen, ...The Journal of Prevention of Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s Disease 9 (2), 197-210, 20222072022
2-)
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trialJ Elkins, R Veltkamp, J Montaner, SC Johnston, AB Singhal, K Becker, ...The Lancet Neurology 16 (3), 217-226, 20171772017
3-)
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trialAL Boxer, I Qureshi, M Ahlijanian, M Grundman, LI Golbe, I Litvan, ...The Lancet Neurology 18 (6), 549-558, 20191112019
4-)
EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s diseaseSB Haeberlein, C Von Hehn, Y Tian, S Chalkias, KK Muralidharan, ...San Diego: 12th Clinical Trials on Alzheimer\'s Disease, 1-25, 2019772019
5-)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsT Plavina, KK Muralidharan, G Kuesters, D Mikol, K Evans, ...Neurology, 10.1212/WNL. 0000000000004485, 2017742017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept